Reaction mixed over FDA committee rejection of MDMA therapy for PTSD
Mental Health Weekly June 14, 2024 Peer reviewed DOI: 10.1002/mhw.34082 via OpenAlex
Summary
The FDA's advisory committee recently rejected the use of MDMA as a treatment for PTSD, stating that there is insufficient evidence to prove its effectiveness. This decision has elicited mixed reactions from professionals in the field and advocacy groups focused on promoting safe access to psychedelic therapies for mental health improvement.
Study at a glance
| Key finding | The FDA found that the evidence does not support the effectiveness of MDMA for treating PTSD. |
|---|
Abstract
A recent decision by the U.S. Food and Drug Administration's (FDA) advisory committee to reject psychedelic treatment and therapy to treat post‐traumatic stress disorder (PTSD), citing that the available evidence of midomafetamine, better known as MDMA, fails to show that the drug is effective, has been met with mixed reaction by a member of the field and an advocacy organization committed to advancing safe and equitable access to psychedelic therapies to improve mental health.